Related Experiment Video

Updated: Dec 7, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K

Designing novel immunocombinations in metastatic renal cell carcinoma

Matteo Santoni1, Francesco Massari2, Gaetano Aurilio3

  • 1Oncology Unit, Macerata Hospital, Macerata, Italy.

Immunotherapy
|October 1, 2020
PubMed

Insights

Immune checkpoint inhibitors and immunocombinations are revolutionizing metastatic renal cell carcinoma (mRCC) treatment. Ongoing trials explore novel immunotherapies, offering new hope for patients with this immunogenic cancer.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has been transformed by immune checkpoint inhibitors.
  • Renal cell carcinoma (RCC) is recognized as a highly immunogenic tumor, making immunotherapy a key treatment strategy.

Purpose of the Study:

  • To review current data on immunocombinations for mRCC.
  • To discuss pivotal clinical trial results for immune checkpoint inhibitors in mRCC.
  • To highlight novel immuno-based treatments under investigation.

Main Methods:

  • Systematic review of pivotal clinical trials involving immune checkpoint inhibitors in mRCC.
  • Discussion of ongoing clinical trials for novel immunotherapies in RCC.

Main Results:

  • Immune checkpoint inhibitors have significantly altered the treatment paradigm for mRCC.
  • Several immunocombinations are showing promise and expanding treatment options.

Conclusions:

  • Immunotherapy, particularly immune checkpoint inhibitors and novel immunocombinations, represents a pivotal and evolving approach for mRCC.
  • Further clinical trials are essential to explore the full potential of these immuno-based treatments.
Keywords:
PD-1PD-L1RCCatezolizumabavelumabimmunotherapyipilimumabnivolumabpembrolizumabrenal cell carcinoma

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.6K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K